tofacitinib우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42552281
Anti-TNF, Pan-JAK, and JAK1-Selective Inhibition Differentially Alter Mechanisms of Flow-Mediated Dilation in Human Microvessels.
Anti-TNF, Pan-JAK, and JAK1-Selective Inhibition Differentially Alter Mechanisms of Flow-Mediated Dilation in Human Microvessels.
- 저자
- Annie Kleynerman Roels, Erin C Birch, Yoshinori Nishijima, Shelby N Hader, Andreas M Beyer, Preetika C Sinh
- 저널
- American journal of physiology. Heart and circulatory physiology
- 공개일
- 2026 Aug 04
- 연구 유형
- 기타
- DOI
- 10.1152/ajpheart.00517.2026
문헌 요약
Patients with chronic inflammatory disorders, including inflammatory bowel disease (IBD), carry an increased risk of cardiovascular disease. The 2022 ORAL Surveillance study reported that the pan-selective Janus kinase inhibitor (JAKi) tofacitinib was associated with increased risk of major adverse cardiovascular events (MACE) among patients with rheumato…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.